Table S1.

Clinical annotation for the discovery set of n = 16 patients screened for PCa

Scano-miR ID	Sample ID	Age, y	Patient diagnosis	Gleason score	PSA, ng/mL	Stage
Aggressive 7	161010S*	58	PCa	9	N/A	II
Aggressive 2	161051S*	60	PCa	8	8	IV
Aggressive 5	16712S*	76	PCa	8	477	Ill
Aggressive 3	16906S*	54	PCa	8	8.53	IV
Aggressive 8	11518552†	66	PCa	9	6.36	N/A
Aggressive 6	11518535†	57	PCa	9	6.8	N/A
Aggressive 4	16847S*	77	PCa	8	45	II
Aggressive 1	11518542†	63	PCa	8	N/A	N/A
Indolent 1	11518536†	71	PCa	6	N/A	N/A
Indolent 4	11518558†	53	PCa	6	N/A	N/A
Indolent 2	11518537†	62	PCa	6	N/A	N/A
Indolent 3	11518539†	73	PCa	6	N/A	N/A
Normal 3	D 2213S†	63	Normal	N/A	N/A	N/A
Normal 4	D 2214S†	66	Normal	N/A	N/A	N/A
Normal 1	D 2218S†	65	Normal	N/A	N/A	N/A
Normal 2	D 2241S/Ac†	60	Normal	N/A	N/A	N/A

The Gleason score is the combined Gleason score obtained through biopsy and histological examination. Clinical tumor stage and cancer staging were based on pathological examination. All samples are serum, male, and Caucasian. N/A, not available.

^*Serum samples were purchased from ProteoGenex, Inc.

^†Serum samples were purchased from ProMedDx, LLC.